Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells ...
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
The Company reported a net loss of $2.4 million in fiscal 2025 or $0.30 per basic and diluted share, compared to net income of $402,000 in fiscal 2024 or $0.05 per basic and diluted share. Due to ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced ...
The Company reported net income of approximately $47,000 or $0.01 per basic and diluted common share for the three months ended February 28, 2026, compared to net income of approximately $283,000, or ...
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results